23andMe Holding Co.(MEHCQ)
USD --+0.00%
Reward39Moderate
Risk64Medium-High
📊75%Data
Thin -135% profit margin · Revenue down 37% YoY
MEHCQ
+0.0 · +0.00%
USD · PINK
23andMe Holding Co. | Healthcare
Earnings Deterioration
Market Cap:96.40M
ℹ️
Reward Rating
39
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
64
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MEHCQ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is 23andMe Holding Co.?

operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally.

MEHCQ · Verdict

Limited reward · elevated risk

MEHCQ stands out on balance sheet and valuation, but watch the volatility signal.

Based on 88% data coverage

MEHCQ · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet72/100

    Current ratio 0.83

  • Valuation67/100

    Above average

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Growth25/100

    Rev -11.3% CAGR · earnings +8.9%

  • Cash flow25/100

    -93% free-cash-flow margin

  • Profitability31/100

    -148% net margin · -406% ROE

Model-based scoring. For information only — not financial advice.

What is 23andMe Holding Co.?

operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 96.40M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap96.40M
P/E RatioN/A
Dividend YieldN/A
52 Week High6.21
52 Week Low0.47
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding25M
No. of Employees257
IndustryDiagnostics & Research
ExchangePINK
Beta2.161
CurrencyUSD